Goldman Sachs analyst Corinne Johnson resumed coverage of Harmony Biosciences (HRMY) with a Neutral rating and $33 price target The firm expects the outlook for the Wakix franchise to remain the driver of the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences Reveals Promising Preclinical Data for BP1.15205
- Harmony Biosciences presents preclinical data for BP1.15205
- Promising Developments in Harmony Biosciences Justify Buy Rating
- Harmony Biosciences settles generic drug litigation, strengthens patent
- Harmony Biosciences Settles Patent Dispute with Lupin